AG Mednet Achieves EU-U.S. Privacy Shield and U.S.-Swiss Privacy Framework Compliance

Taking steps to further enhance medical data protection, AG Mednet is now EU-U.S. Privacy Shield-Certified and U.S.-Swiss Privacy Framework compliant via self-certification. AG Mednet technology is used in clinical trials in more than 80 countries including most European Union nations. The company is committed to the highest levels of data protection available to its customers in the EU and around the globe.“We’ve built our business around the idea that data quality matters. Within clinical trials, data quality and the privacy of that data means everything, and often determines the success or failure of a trial,” said Abraham Gutman, AG Mednet president and CEO. “While collecting patient data is critical to advancing many clinical trials, ensuring that patient data is protected is equally vital.”The EU-U.S. and Swiss-U.S. Privacy Shield Frameworks were designed by the U.S. Department of Commerce and the European Commission and Swiss Administration to provide companies on both sides of the Atlantic with a mechanism to comply with data protection requirements when transferring personal data from the European Union and Switzerland to the U.S. This policy replaces the International Safe Harbor Privacy Principles.For more information, visit www.agmednet.com.About AG MednetAG Mednet is the leading quality compliance partner for image data submission and collection, as well as endpoint and adverse event adjudication workflows. The company is a proponent of zero-delay clinical trials. The company has supported more than 850 global imaging trials. Dozens of adjudication protocols are being managed by sponsors and CROs using Judi. More than 45,000 registered users across thousands of investigator sites in more than 80 countries use AG Mednet to submit more than 10,000,000 images per month and adjudicate hundreds of events in projects sponsored by each of the world’s top 20 pharmaceutical, biotech and medical device companies.

Around the web

Given the precarious excitement of the moment—or is it exciting precarity?—policymakers and healthcare leaders must set directives guiding not only what to do with AI but also when to do it. 

The final list also included diabetes drugs sold by Boehringer Ingelheim and Merck. The first round of drug price negotiations reduced the Medicare prices for 10 popular drugs by up to 79%. 

HHS has thought through the ways AI can and should become an integral part of healthcare, human services and public health. Last Friday—possibly just days ahead of seating a new secretary—the agency released a detailed plan for getting there from here.